Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-01-14
2011-12-13
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S308700
Reexamination Certificate
active
08076366
ABSTRACT:
Novel polymorphic forms of bendamustine free base are described, including amorphous bendamustine free base, six anhydrous crystalline forms, four hydrate forms, and five solvate forms, with methods of their preparation and use also being described.
REFERENCES:
patent: 5204335 (1993-04-01), Sauerbier et al.
patent: 5227373 (1993-07-01), Alexander et al.
patent: 5750131 (1998-05-01), Wichert et al.
patent: 5770230 (1998-06-01), Teagarden et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5972912 (1999-10-01), Marek et al.
patent: 6034256 (2000-03-01), Carter et al.
patent: 6077850 (2000-06-01), Carter et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6271253 (2001-08-01), Carter et al.
patent: 6380210 (2002-04-01), Desimone et al.
patent: 6492390 (2002-12-01), Carter et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6569402 (2003-05-01), Cheesman et al.
patent: 6573292 (2003-06-01), Nardella
patent: 6613927 (2003-09-01), Kwok
patent: 2003/0232874 (2003-12-01), Nardella
patent: 2004/0053972 (2004-03-01), Narn
patent: 2004/0058956 (2004-03-01), Akiyama et al.
patent: 2004/0072889 (2004-04-01), Masferrer
patent: 2004/0096436 (2004-05-01), Carson et al.
patent: 2004/0152672 (2004-08-01), Carson et al.
patent: 2004/0247600 (2004-12-01), Leoni
patent: 2005/0020615 (2005-01-01), Rubino
patent: 2005/0060028 (2005-03-01), Horres et al.
patent: 2005/0176678 (2005-08-01), Horres et al.
patent: 2006/0051412 (2006-03-01), Petereit et al.
patent: 80967 (1895-04-01), None
patent: 159877 (1905-04-01), None
patent: 293808 (1916-08-01), None
patent: 159289 (1983-03-01), None
patent: 10016077 (2001-12-01), None
patent: 10306724 (2003-09-01), None
patent: 10304403 (2004-08-01), None
patent: 0656211 (1999-06-01), None
patent: 1354952 (2003-10-01), None
patent: 1444989 (2004-08-01), None
patent: 96/28148 (1996-09-01), None
patent: 96/28148 (1996-09-01), None
patent: 03/066027 (2003-08-01), None
patent: 03/081238 (2003-10-01), None
patent: 03/081238 (2003-10-01), None
patent: 03/086470 (2003-10-01), None
patent: 03/086470 (2003-10-01), None
patent: 03/094990 (2003-11-01), None
patent: 2006/076620 (2006-07-01), None
patent: 2006/076620 (2006-07-01), None
Aivado et al., “Bendamustine in the Treatment of Chronic Lymphocytic Leukemia: Results and Future Perspectives”, Seminars in Oncology, 2002, 29(4) 19-22.
Author Unknown, “Ribomustin: Bendamustine Product Monograph”, Ribosepharm GMBH, Munchen Germany, Jan. 2002, 59 pages.
Author Unknown, “Ribomustin: Bendamustine Product Monograph”, Ribosepharm GMBH, Munchen Germany, Mar. 2005, 72 pages.
Barman et al., “Bendamustine” Drugs, 2001, 61(5), 631-638, Auckland, New Zealand.
Bremer, “High Rates of Long-lasting remissions after 5-day bendamustine Chemotherapy Cycles in Pre-Treated low-grade non-hodgkin's-lymphomas”, Journal of Cancer Research and Clinical Oncology, 2002 , 128(11), 603-609.
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 1995, 12(7), 945-954.
Chow et al., “Anti-CD20 Antibody (DEC-C2B8, rituximab) enhances efficiency of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of Cytokines complement and caspases”, Hematologica, Jan. 2002, 87(1), 33-43.
Chow et al., “In AML Cell Lines Ara-C combined with Purine Analogues is able to Exert Synergistic as well as Antagnostic Effects on Proliferation Apoptosis and Disruption of Mitochondrial Membrane Potential”, Leukemia & Lymphoma, 2003, 44(1), 165-173.
Chow et al., “In Vitro Induction of Apoptosis of Neoplastic Cells in Low-Grade non-Hodgkin's Lymphomas by Combination of established cytotoxic drugs with bendamustine”, Hematologica, 2001, 86(5), 485-493.
Chow et al., “Synergistic Effects if Chemotherapeutic Drugs in Lymphoma Cells are associated with down-regulation if inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4(Par-4), death-associated protein (Dazz) and with enforced caspase activation”, Biochemical Pharmacology, 2003, 66(5), 711-724.
Diehl et al., “Bendamustine in the Treatment of Hematologic Malignancies”, Semin. Oncol., Suppl. 13, 2002, Saundes, Philadelphia, 29(4), 3 pages.
Fichtner et al., “Antineoplastic Activity and Toxicity of some Alkylating Cytostatics (Cyclophosphamide, CCNU, Cytostasan) Encapsulated in Liposomes in different murine tumor models”, Journal of Microencapsulation, 1986, 3(2), 77-87.
Ghandi, “Metabolism and Mechanisms of Action of Bendamustine: Rationales for Combination therapeutics”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 4-11.
Gust et al., “Investigation on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type I. Synthesis, Isolation and Characterization if Reference Substances”, Monatshefte fur Chemie, 1997, 128(3), 291-299.
Heider et al., “Efficacy and Toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas”, Anti-Cancer Drugs, 2001, 12(9), 725-729.
Kath et al., “Bendamustine Monotherapy in advanced and refractory chronic lymphocytic Leukemia”, Journal of Cancer Research and Clinical Oncology, 2001, 127(1), 48-54.
Koenigsman et al., “Fludarabine and Bendamustine in Refractory and Relapsed Indolent Lymphoma—a Multicenter Phase I/II Trial of the East German Society of Hematology and Oncology (OSHO)”, Leukemia & Lymphoma, 2004, 45 (9), 1821-1827.
Koester et al., “Carboplatin in Combination with bendamustine in previously untreated patients with extensive-stage small lung cancer (SCLC)”, Clinical Drug Investigation, 2004, 24(10), 611-618.
Kollmannsberger et al., “Phase II study of Bendamustine in Patients with relapsed or cisplatin-refractory germ cell Cancer”, Anti-Cancer Drugs, 2000, 11(7), 535-539.
Konstantinov et al., “Cytotoxic Efficacy of Bendamustine in Human Leukemia and Breast Cancer cell lines”, Journal of Cancer Research and Clinical Oncology, 2002, 128(5), 271-278.
Leoni et al., “Sdx-105 (Trenda), Active in Non-Hodgkin's Lymphoma Cells, Induces the Mitotic Catastrophe Death Pathway”, Blood, 2004, 104(11), (Abstract).
Maas, “Stability of Bendamustine Hydrochloride in Infusion Solutions”, 1994, 49(10), 9 pages.
Niemeyer et al., “SDX-105 (bendamustine) is a Clinically active Chemotherapeutic agent with a distinct mechanism of action”, Proc Annu Meet Am Assoc Cancer Res., 2004, 45(1), 2 pages.
Nowak et al, “Upon Drug-Induced Apoptosis in Lymphoma Cells X-linked Inhibitor of Apoptosis (XIAP) Translocates from the Cytosol to the Nucleus”, Leukemia & Lymphoma, 2004, 45(7), 1429-1436.
Ponisch et al., “Bendamustine in the Treatment of Multiple Myeloma: Results and Future Perspectives”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 23-26.
Preiss et al., “Pharmacokinetics of bendamustine (Cytostasan) in patients”, Pharmazie, 1985, 40(11), 782-784.
Rummel et al., “Bendamustine in the Treatment of Non-Hodgkin's Lymphoma: Results and Future Perspectives”, Seminars in Oncology, Suppl. 13, 2002, 29(4), 27-32.
Rummel et al., “In Vitro Studies with Bendamustine: Enhanced Activity in Combination with Rituximab”, Seminars in Oncology, Suppl. 13, Aug. 2002, 29(4), 12-14.
Scasnar et al., “Radiochemical Assay of Stability of 14C-Cytostasan Solutions During Preparation and Storage”, 1988, 121(2m), 489-497.
Schmidt-Hieber et al., “A Phase II Study of bendamustine Chemotherapy as Second-line treatment in metastatic uveal Melanoma”, Melanoma Research, 2004, 14(6), 439-442.
Schoffski, “Repeated Administration of Short Infusions of Bendamustine: A phase I study in Patients with Advanced Progressive Solid Tumors”, Journal of Cancer Research and Clinical Oncology, 2000, 126(1), 41-47.
Schrijvers et al., “Phas
Courvoisier Laurent D.
Eddleston Mark
Haltiwanger R. Curtis
McKean Robert E.
Anderson Rebecca
Cephalon Inc.
Shterengarts Samantha
LandOfFree
Forms of bendamustine free base does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Forms of bendamustine free base, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Forms of bendamustine free base will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4308090